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Hereditary angioedema (HAE) is a rare autosomal dominant disease most commonly associated with defects in
C1 esterase inhibitor (C1-INH). HAE manifests as recurrent episodes of edema in various body locations. Atypical
symptoms, such as ascites, acute respiratory distress syndrome, and hypovolemic shock, have also been reported.
Management of HAE conventionally involves the treatment of acute attacks, as well as short- and long-term
prophylaxis. Since attacks can be triggered by several factors, including stress and physical trauma, prophylactic
therapy is recommended for patients undergoing surgery. Human plasma-derived C1-INH (pdC1-INH) concentrate
is indicated for the treatment of both acute HAE attacks and pre-procedure prevention of HAE episodes in patients
undergoing medical, dental, or surgical procedures. We report the first case of a patient with HAE who experienced
an abdominal attack precipitated by a retroperitoneal bleed while being converted from warfarin to heparin in
preparation for surgery. Subsequently, the patient had a protracted course in hospital with other complications,
which included hypovolemic shock, ascites, severe sepsis from nosocomial pneumonia, renal and respiratory failure.
Despite intensive interventions, the patient remained in a critical state for months; however, after a trial of daily
intravenous infusion of pdC1-INH concentrate (Berinert®, CSL Behring GmbH, Marburg, Germany), clinical status
improved, particularly renal function. Therefore, pdC1-INH concentrate may be an effective treatment option to consider
for critically-ill patients with HAE.
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Hereditary angioedema (HAE) is an autosomal dom-
inant genetic disease affecting approximately 1 in 50,000
people worldwide, with no ethnic differences reported [1].
Recently, a new classification system has been described
for angioedema and this case report focuses on hereditary
angioedema with C1 esterase inhibitor (C1-INH) defi-
ciency [2]. This rare disease is due to a mutation in one of
the alleles of the C1-INH gene, SERPING1, which results
in reduced plasma levels of C1-INH and dysregulation of* Correspondence: hpham@uottawa.ca
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unless otherwise stated.the contact system, facilitating an increased release of
bradykinin, the key mediator of angioedema.
C1-INH plays an important role in downregulating
several interconnected pathways including the comple-
ment, contact, fibrinolytic, and coagulation systems [3].
Activation of these systems whether by trauma, infec-
tion, febrile illness, or other unknown factors consumes
C1-INH as it is a ‘suicide inhibitor’ [4].
HAE is characterized by recurrent episodes of local-
ized non-pruritic edema, painful abdominal attacks, and
angioedema of the upper airway [5]. Laryngeal swelling
poses the greatest risk to patient health, and can lead to
death from upper airway obstruction. Attacks can be
triggered by several factors, including stress, physicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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In many cases, attacks are preceded by prodromal symp-
toms such as fatigue, irritability, weakness, nausea, and
erythema marginatum [6]. Swelling sometimes occurs
rapidly, but typically worsens gradually over the first
24 hours. Attacks can last for 1–5 days, and usually resolve
over 48–72 hours [5,7]. The frequency of attacks, sites of
edema, and precipitating events can vary widely, both
between individuals and within the same patient [5,7].
In addition to the common clinical presentations de-
scribed above, there have been case reports of HAE being
associated with some severe conditions: acute respiratory
distress syndrome (ARDS) [8], ascites [9-14], and hypo-
volemic shock [15]. The pathophysiology of these associa-
tions has not been adequately elucidated yet.
Management of HAE involves the treatment of acute
attacks, as well as short- or long-term prophylaxis. Sev-
eral effective HAE treatments are available, and various
international guidelines and recommendations have been
published to inform their optimum use [1,6,16,17].
However, low awareness of HAE often leads to delayed,
suboptimal, or lack of treatment. This can result in un-
necessary morbidity and, in some instances, fatality.
Furthermore, as HAE is a systemic disease, the treat-
ment of comorbid conditions and routine medical proce-
dures can pose a problem, which may require intervention
to prevent attacks [17,18]. Surgery is a particular concern
for patients with HAE, as retrospective studies have shown
an increased risk of upper airway angioedema complica-
tions, especially with oral surgeries [19]. Several agents are
recommended for short-term prophylaxis to prevent
attacks during major surgery, though plasma-derived
CI-INH (pdC1-INH) concentrates (Berinert®, CSL Behring
GmbH, Marburg, Germany and Cinryze®, ViroPharma,
Exton PA, USA and ViroPharma Europe, Brussels,
Belgium) are generally the favored options [17]. The 2012
World Allergy Organization recommended dose of intra-
venous (IV) pdC1-INH for acute attack is 20 units/kg
(Berinert®) or 1000 units (Cinryze®) [17]. For short-term
prophylaxis, guideline suggestions vary between 10-20
units/kg or 1000 units, 1–6 hours before the procedure
[17]. Alternatively, attenuated androgens can also be used
for short-term/pre-procedural prophylaxis for 5 days
before and 2–5 days after the event with danazol at
2.5–10 mg/kg/day (maximum of 600 mg) or stanozolol
at 4–6 mg/day [17].
Berinert® (CSL Behring GmbH, Marburg, Germany) is
a highly purified pdC1-INH concentrate that treats the
root cause of HAE symptoms by replacing the deficient
or dysfunctional C1-INH. In Europe, pdC1-INH concen-
trate is indicated for the treatment of both acute HAE
attacks and pre-procedure prevention of acute episodes
of HAE in adult and pediatric patients undergoing med-
ical, dental, or surgical procedures [20]. The efficacy andsafety of pdC1-INH concentrate for the long-term treat-
ment of successive HAE attacks at different anatomical
sites has been demonstrated in numerous observational
and descriptive studies [21].
Here we describe the use of pdC1-INH concentrate
(Berinert®) in a patient with HAE with comorbidities
who developed major complications prior to scheduled
heart surgery, including retroperitoneal bleed, hypo-
volemic shock, ascites, severe sepsis from nosocomial
pneumonia, renal and respiratory failure.
Case presentation
Patient history
This case report involves a 51-year-old man with type I
HAE, who first developed symptoms in his late teens.
No genetic testing had been carried out, but laboratory
tests showed a C1-INH level of 73 mg/L and a C4 level
of <0.10 g/L, which are both below the normal ranges
of 210–350 mg/L and 0.16–0.47 g/L, respectively. In
addition to HAE, the patient also suffered from the
neurological disorder Charcot-Marie-Tooth disease, and
congenital aortic stenosis. His sister also had both HAE
(age of onset also in late teens) and Charcot-Marie-
Tooth disease [22]. The patient was experiencing frequent
attacks of abdominal HAE, occurring approximately every
4–6 weeks.
Surgical history
In 1997, the patient underwent successful open-heart
surgery (aortic stenosis repair). In preparation for the
surgery, the patient was receiving oral danazol (200 mg,
three times a day). He was also given one dose of 1500
units IV pdC1-INH concentrate preoperatively (his weight
was approximately 78 kg). The patient was satisfied with
the outcome and his quality of life was substantially
improved.
In 2000, the patient required emergency surgery due
to an extensive ascending aorta aneurysm dissection.
Surgery lasting 12 hours was carried out to replace the
ascending aorta. At the time of operation, he was receiv-
ing oral stanozolol (4 mg, four times a day), as the
surgeon chose to prescribe stanozolol over danazol. This
higher than normal dosing was only prescribed for
1 week in preparation for the emergency surgery (4–
6 mg/day is the norm). Stanozolol was reduced to 12 mg
daily after about 1 month and then tapered down to
4 mg daily shortly after that. The operation had a suc-
cessful outcome. Postoperatively, he had an abdominal
HAE attack and was treated with 1500 units of IV pdC1-
INH concentrate.
Surgical complications
In 2004, the patient was admitted for a scheduled
aortic aneurysm repair. He was receiving oral danazol
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from the market at this time. However, the procedure was
cancelled as complications arose 3 days before the
scheduled surgery; hence, no prophylactic C1-INH had
been provided.
In preparation for the surgery, the patient’s anticoagu-
lation was bridged from long-term warfarin to heparin.
Three days into his heparin protocol, the patient com-
plained of left flank pain and severe abdominal pain. On
physical examination, the patient was agitated, dis-
oriented, pale, and peripherally cold. His vital signs con-
sisted of a temperature (temp) of 35.2°C, heart rate (HR)
of 91 beats per minutes (bpm), blood pressure (BP) of 70/
40 mm Hg, and respiratory rate (RR) of 26 breaths/min.
Laboratory results revealed low hemoglobin at 43 g/L
(was 118 g/L 2 days prior), low hematocrit of 0.24,
leukocytosis at 22 × 109/L, hyperglycemia at 8.6 mmol/L,
and acute renal failure with creatinine (Cr) at 290 umol/L
(up from 64 umol/L 5 days earlier) and zero urine output.
Resuscitation interventions included discontinuation of
heparin, sedation with propofol, intubation, mechanical
ventilation (FiO2 = 0.40, PEEP = 10), and renal replacement
therapy (RRT). Red blood cells, IV fluids, norepinephrine
(vasopressor), and pdC1-INH concentrate (2000 units)
were also administered. An abdominal computed tomog-
raphy (CT) scan showed a massive retroperitoneal
hemorrhage, slight intraperitoneal bleeding, and mod-
erate ascites. Ascites was clinically confirmed the following
morning as the patient had asymmetric abdomen disten-
tion and tautness in the right and left upper quadrants
with rebound tenderness and guarding in the right lower
quadrant. His abdominal girth at this time was 106 cm.
The care team had the clinical impression that the patient
had an HAE abdominal crisis precipitated by a spontan-
eous retroperitoneal bleed followed by the development of
ascites, hypovolemic shock, and acute renal failure. Repeat
CT scan revealed the retroperitoneal hematoma was stable,
organized, and contained.
Two days later, the patient contracted hospital-acquired
pneumonia (subsequently shown to be caused by Klebsiella
pneumoniae, Staphylococcus aureus, and Pseudomonas
aeruginosa).
A chest x-ray (CXR) showed extensive bilateral pneu-
monia. The patient was treated with different anti-
biotics (ciprofloxacin, piperacillin/tazobactam, vancomycin,
metronidazole, cloxacillin, rifampin, and tobramycin) over
the next few weeks in attempts to clear up the bacterial
infection.
Simultaneously with regard to renal function, the patient
was diagnosed with ischemic acute tubular necrosis. Renal
function improved for a short time following the initial
RRT with Cr trending down to 124 umol/L, but 7 days
after the initial bleed, renal function deteriorated again
with Cr rising to 139 umol/L, most likely due to increasingsepsis as the patient developed a temp of 40.4°C, HR of
138 bpm, BP of 115/50 mmHg, RR of 27 breaths/min, and
leukocytosis of 30.3 × 109/L. This second round of acute
kidney injury necessitated reinitiating RRT 2 days later, as
Cr reached 322 umol/L. Three days later, the patient’s asci-
tes, which had begun to resolve, started to increase again
in the absence of new bleed (according to a CT scan). The
next day, dialysis became clinically indicated. In addition to
worsening kidney function, the patient showed signs of
hypoxemic respiratory failure with mild oxygen desatur-
ation (93–97%) despite being on a bi-level ventilator. Two
days later, the respiratory failure required a tracheotomy
for assisted ventilation. His active pneumonia was impli-
cated as the suspected source of the severe sepsis.
However, the care team’s differential diagnosis for the hyp-
oxemic respiratory failure consisted of extensive nosoco-
mial pneumonia, severe sepsis from the pneumonia,
ARDS, or a combination of the three. Discerning between
the three processes was a challenge because they were
highly interrelated. Severe pneumonia and sepsis can cause
ARDS while severe sepsis and ARDS can lead to multisys-
tem dysfunction. Furthermore, severe pneumonia and
ARDS share similar symptoms, signs, and radiographic
findings (i.e. the patient’s CXR showed bilateral patchy in-
filtrates which could be due either to pneumonia or alveo-
lar pulmonary edema). Over the course of the following
weeks, the patient continued to experience renal failure
requiring dialysis up to 4 times a week.
Despite 2 months of optimal intensive care unit (ICU)
interventions including renal dialysis, assisted ventila-
tion, antibiotic therapy, blood transfusions, daily danazol
(200 mg), and very conservative intermittent pdC1-INH
concentrate, the patient remained in critical condition and
the decision to terminate his life was considered. Given a
lack of clinical and hemodynamic response to ongoing
conventional treatment, a decision was made to administer
daily pdC1-INH concentrate as a trial to see if the multi-
organ failure and ascites would be alleviated with better
control the patient’s HAE via C1-INH replacement. An IV
infusion of pdC1-INH concentrate (1000 units) was
administered for 21 days (total: 21000 units).
Within 48 hours of daily pdC1-INH concentrate infu-
sion, renal function improved (improved urine output
and stabilization of Cr levels). After 4 more days, Cr
values started decreasing. Eventually, abdominal ascites
and pneumonia clinically resolved as well. The care team
successfully weaned him off the respirator. The patient
regained his full strength after further reconditioning
and returned home 4 months after being admitted for
aortic aneurysm repair.
Discussion and conclusions
Given the role of C1-INH in various pathways and tre-
mendous physiologic stress of this patient’s lengthy stay
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toneal hemorrhage, hypovolemic shock, ascites, renal
failure, nosocomial pneumonia, severe sepsis, and
hypoxemic respiratory failure), it is likely that HAE was
inadequately controlled, resulting in multiple relapses in
this context of critical illness. Treatment with daily
infusions of pdC1-INH concentrate optimized control
of HAE.
Although the anti-inflammatory role of C1-INH ther-
apy has been explored mostly in animal studies, there
have been some studies in which the therapeutic admin-
istration of pdC1-INH concentrate may have beneficial
effects on patients in a variety of clinical scenarios, even
non-HAE patients. These include conditions such as
sepsis, ischemia-reperfusion injury, emergency coronary
artery bypass grafting, transplantation [23]; septic shock,
vascular leak syndrome, severe thermal injury [24]; and
toxic shock syndrome [25]. In a double blind, random-
ized placebo-controlled trial of 40 patients with severe
sepsis and septic shock, investigators infused patients
over 1 hour with pdC1-INH concentrate IV, starting
with 6000 units, followed by 3000, 2000, and 1000 units
(total: 12000 units) at 12-hour intervals. Patients treated
with pdC1-INH concentrate had less severe multi-organ
dysfunction and significantly improved renal function
compared with patients treated with placebo [26]. In the
same group of patients, researchers found that neutro-
phil activation, which is elevated in sepsis and correlated
with severity of organ dysfunction, was reduced by C1-
INH therapy. This could partially account for the mildly
beneficial treatment effects on organ dysfunction in sep-
sis [27]. With respect to survival, pdC1-INH concentrate
infusion of 12000 units (6000 units/day for 2 days) in-
creased survival rates for patients with sepsis through
downregulation of the systemic inflammatory response
[28]. In terms of renal function, the investigators were un-
certain as to whether C1-INH improved kidney function
through local inhibition of complement and contact activa-
tion or by prevention of extensive capillary leakage [26].
In a previous report, a young woman with Caroli’s dis-
ease suffering from septic shock with capillary leakage
syndrome, had received ultimate rescue therapy con-
sisting of 60 units/kg pdC1-INH concentrate infusion
over 1 hour followed by continuous administration of
30 units/kg pdC1-INH concentrate per day for 4 days.
Her hemodynamics rapidly stabilized with a reduction
in vasopressor medication and normalization of fluid
balance [29].
In another small clinical trial of seven patients with
streptococcal toxic shock syndrome (septic shock with
multi-organ failure), all patients received 2–3 high doses
of pdC1-INH totaling 6000–10000 units within the first
24 hours after admission. A marked shift of fluid from the
extravascular to intravascular compartment was observed(in all but one patient); leading to transient pulmonary
edema but also a rapid decrease in the need for vasopres-
sors and fluid replacement [25].
Thus, this literature, whereby even non-HAE patients
gained treatment benefits from C1-INH therapy in a
number of critical conditions, helps generate hypotheses
to explain some of the treatment benefits of daily infu-
sion of pdC1-INH observed in this case report patient.
Furthermore, the long-standing history of HAE in this
patient and the fact that he had benefited from the use
of pdC1-INH infusion during the previous two major
surgical interventions in 1997 and 2000, provided fur-
ther support that C1-INH infusion likely facilitates much
greater control of HAE.
In summary, here we report the first case of HAE with
pre-surgical multi-organ failure and significant ascites,
likely due to an abdominal HAE attack. The patient
responded to IV infusion of pdC1-INH concentrate
(1000 units), administered daily for 21 days. Daily IV in-
fusion of pdC1-INH concentrate, in addition to conven-
tional supportive measures, may be an effective option
to consider in preventing complications in critically ill
patients with HAE. As shown in this case report, HAE
can be potentially life-threatening. It is important for
patient/family and treating physicians to be aware of this
outcome, in order to prevent future occurrences. Lack
of awareness of HAE may have contributed to a delay in
treatment and unnecessary suffering. Furthermore, the
outcome in this case would most likely have been fatal
without pdC1-INH concentrate. This case highlights
the need to raise the profile of HAE within the medical
community.Consent
Written informed consent was obtained from the next
of kin of the patient for publication of this case report
and any accompanying images. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.Abbreviations
ARDS: Acute respiratory distress syndrome; BP: Blood pressure; bpm: Beats
per minute; C1-INH: C1 esterase inhibitor; Cr: Creatinine; CT: Computed
tomography; CXR: Chest x-ray; FiO2: Fraction of inspired oxygen;
HAE: Hereditary angioedema; HR: Heart rate; ICU: Intensive care unit;
IV: Intravenous; PEEP: Positive end-expiratory pressure; pdC1-INH: Plasma-
derived C1-INH; RR: Respiratory rate; RRT: Renal replacement therapy;
temp: Temperature.Competing interests
Hoang Pham has no competing interests to declare. Stephanie Santucci has
served as a member of nursing national advisor board for CSL Behring on
self-infusion. William H. Yang has served as a member of national advisory
boards for CSL Behring, and received unrestricted educational grants to
attend CHE events, and research grants for research on acute HAE attacks
(but not for short-term prophylaxis treatment).
Pham et al. Allergy, Asthma & Clinical Immunology 2014, 10:62 Page 5 of 5
http://www.aacijournal.com/content/10/1/62Authors’ contributions
HP: Collecting the clinical, laboratory and radiographic images/data, drafting
and approving the manuscript. SS: Assisted in the care of the subject,
obtaining the verbal and written informed consent, drafting the manuscript,
collecting data from the hospital records and private office. Choosing journal
and approving the final draft. WHY: Physician responsible in the ongoing
care of the subject. Concept and design of the original and ongoing draft,
collecting data from the hospital records and private office, obtaining verbal
and written consent from the family member. Interpretation of the clinical,
laboratory, and radiologic data. Choosing journal and approving the final
draft. All authors read and approved the final manuscript.
Acknowledgment
We are grateful for the assistance of Rachel Harrison and the staff from Yang
Medicine for collecting the data and the preparation of this manuscript. In
particular, we are grateful to the patient’s family for their dedication and
willingness to provide information to make this manuscript possible. Also,
we are indebted for the excellent patient care and collaboration of the
surgeons, doctors, radiologists, nurses, and intensive care unit staff at the
Heart Institute, The Ottawa Hospital. Editorial support was provided by Karen
Yee, PhD, of Fishawack Communications Ltd, funded by CSL Behring.
Author details
1Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. 2Allergy
& Asthma Research Centre, Ottawa, Ontario, Canada.
Received: 16 May 2014 Accepted: 20 November 2014
References
1. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, Aygoeren-
Pursun E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar D,
Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons H,
Mace S, Mako B, Neurath D, Poon MC, Rivard GE, Schellenberg R, Rowan D,
Rowe A, et al: 2010 International consensus algorithm for the diagnosis,
therapy and management of hereditary angioedema. Allergy Asthma Clin
Immunol 2010, 6:24.
2. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T,
Farkas H, Grumach A, Kaplan AP, Riedl MA, Triggiani M, Zanichelli A, Zuraw B:
Classification, diagnosis, and approach to treatment for angioedema:
consensus report from the Hereditary Angioedema International Working
Group. Allergy 2014, 69(5):602–616.
3. Davis AE 3rd: Hereditary angioedema: a current state-of-the-art review, III:
mechanisms of hereditary angioedema. Allergy Asthma Clin Immunol 2008,
100(1 Suppl 2):S7–S12.
4. Davis AE 3rd: The pathophysiology of hereditary angioedema. Clin Immunol
2005, 114(1):3–9.
5. Bork K, Davis-Lorton M: Overview of hereditary angioedema caused
by C1-inhibitor deficiency: assessment and clinical management.
Eur Ann Allergy Clin Immunol 2013, 45:7–16.
6. Lang DM, Aberer W, Bernstein JA, Chng HH, Grumach AS, Hide M, Maurer M,
Weber R, Zuraw B: International consensus on hereditary and acquired
angioedema. Ann Allergy Astham Immunol 2012, 109:395–402.
7. Ghazi A, Grant JA: Hereditary angioedema: epidemiology, management,
and role of icatibant. Biologics 2013, 7:103–113.
8. da Costa JT, da Silva JM, Cunha L, Castel-Branco MG, Azevedo MV: Hereditary
angioedema presenting with adult respiratory distress syndrome. Chest 1994,
105:1898–1899.
9. Salamon L, Morovic-Vergles J: Initial presentation of hereditary angioedema as
abdominal pain and ascites in puerperium: case report. Acta Dermatovenerol
Croat 2010, 18:261–263.
10. Branco-Ferreira M, Pedro E, Barbosa MA, Carlos AG: Ascites in hereditary
angioedema. Allergy 1998, 53:543–545.
11. Jesic R, Culafic D, Bonaci-Nikolic B: Hereditary angioedema presenting
with recurrent ascites. Dig Dis Sci 2005, 50:24–26.
12. Shinzato T, Nakamura H, Kuniyoshi T, Higashionna A, Uehara T, Oshiro J,
Uechi H, Shikiya K, Sakugawa H, Kinjo F, Saito A: Hereditary angioedema:
a case with ascites yet no symptoms in the family. Intern Med 1992,
31:633–635.
13. Shah TJ, Knowles WO, McGeady SJ: Hereditary angioedema with recurrent
abdominal pain and ascites. J Allergy Clin Immunol 1995, 96:259–261.14. Talavera A, Larraona JL, Ramos JL, Lopez T, Maraver A, Arias J, Barrios A:
Hereditary angioedema: an infrequent cause of abdominal pain with
ascites. Am J Gastroenterol 1995, 90:471–474.
15. Cohen N, Sharon A, Golik A, Zaidenstein R, Modai D: Hereditary
angioneurotic edema with severe hypovolemic shock. J Clin
Gastroenterol 1993, 16:237–239.
16. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B:
Evidence-based recommendations for the therapeutic management of
angioedema owing to hereditary C1 inhibitor deficiency: consensus report
of an International Working Group. Allergy 2012, 67:147–157.
17. Craig T, Pursun EA, Bork K, Bowen T, Boysen H, Farkas H, Grumach A,
Katelaris CH, Lockey R, Longhurst H, Lumry W, Magerl M, Martinez-Saguer I,
Ritchie B, Nast A, Pawankar R, Zuraw B, Maurer M: WAO guideline for the
management of hereditary angioedema. World Allergy Organ J 2012,
5:182–199.
18. Grant JA, White MV, Li HH, Fitts D, Kalfus IN, Uknis ME, Lumry WR:
Preprocedural administration of nanofiltered C1 esterase inhibitor to
prevent hereditary angioedema attacks. Allergy Asthma Proc 2012,
33:348–353.
19. Farkas H, Zotter Z, Csuka D, Szabó E, Nébenfűhrer Z, Temesszentandrási G,
Jakab L, Varga L, Harmat G, Karádi I: Short-term prophylaxis in hereditary
angioedema due to deficiency of the C1-inhibitor–a long-term survey.
Allergy 2012, 67(12):1586–1593.
20. CSL Behring: CSL Behring Receives European Health Authorities’ Approval
of Berinert® for Short-Term Prophylaxis in Adults and Children. [http://
www.cslbehring.com/newsroom/Berinert-Wins-EMA-Approval-for-Short-
Term-Prophy-Label?tabSelections=1255923338766&currentPage=1]
21. Bork K, Steffensen I, Machnig T: Treatment with C1-esterase inhibitor
concentrate in type I or II hereditary angioedema: a systematic literature
review. Allergy Asthma Proc 2013, 34:312–327.
22. Fernandez PG, Day JH, Simpson NE, Zachariah PK: Hereditary angioneurotic
edema and Charcot-Marie-Tooth disease in the same family. Can Med
Assoc J 1978, 119(5):455–458.
23. Singer M, Jones AM: Bench-to-bedside review: the role of C1-esterase
inhibitor in sepsis and other critical illnesses. Crit Care 2011, 15:203.
24. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE:
C1-Esterase inhibitor: an anti-inflammatory agent and its potential
use in the treatment of diseases other than hereditary angioedema.
Pharmacol Rev 2000, 52:91–112.
25. Fronhoffs S, Luyken J, Steuer K, Hansis M, Vetter H, Walger P: The effect of
C1-esterase inhibitor in definite and suspected streptococcal toxic shock
syndrome. Report of seven patients. Intensive Care Med 2000, 26:1566–1570.
26. Caliezi C, Zeerleder S, Redondo M, Regli B, Rothen HU, Zurcher-Zenklusen R,
Rieben R, Devay J, Hack CE, Lammle B, Wuillemin WA: C1-inhibitor in
patients with severe sepsis and septic shock: beneficial effect on
renal dysfunction. Crit Care Med 2002, 30:1722–1728.
27. Zeerleder S, Caliezi C, van Mierlo G, Eerenberg-Belmer A, Sulzer I, Hack CE,
Wuillemin WA: Administration of C1 inhibitor reduces neutrophil activation
in patients with sepsis. Clin Diagn Lab Immunol 2003, 10:529–535.
28. Igonin AA, Protsenko DN, Galstyan GM, Vlasenko AV, Khachatryan NN,
Nekhaev IV, Shlyapnikov SA, Lazareva NB, Herscu P: C1-esterase inhibitor
infusion increases survival rates for patients with sepsis*. Crit Care Med
2012, 40:770–777.
29. Marx G, Nashan B, Cobas Meyer M, Vangerow B, Schlitt HJ, Ziesing S,
Leuwer M, Piepenbrock S, Rueckoldt H: Septic shock after liver
transplantation for Caroli’s disease: clinical improvement after
treatment with C1-esterase inhibitor. Intensive Care Med 1999,
25:1017–1020.
doi:10.1186/s13223-014-0062-9
Cite this article as: Pham et al.: Successful use of daily intravenous
infusion of C1 esterase inhibitor concentrate in the treatment of a
hereditary angioedema patient with ascites, hypovolemic shock, sepsis,
renal and respiratory failure. Allergy, Asthma & Clinical Immunology
2014 10:62.
